Aquaporin 4 antibody–positive patients with NMO or NMO spectrum disorder are at high risk for relapse and severe vision and motor impairments.
Investigators in the United Kingdom and Japan detail the clinical outcomes and prognostic features for 106 patients with neuromyelitis optica (NMO) or NMO spectrum disorder and positive aquaporin-4 (AQP4) antibody testing. NMO includes optic neuritis (ON) and longitudinally extensive transverse myelitis (LETM) with AQP4 antibodies and a nonspecific brain MRI. NMO spectrum disorder includes ON or LETM (but not both), along with antibodies and nonspecific MRI.
Median disease duration was 75 months (range, 3–417 months); 87% were women. The overall mean age of onset was 41 years; mean age at onset was earlier for ON (37) and later for LETM (46). Simultaneous ON and transverse myelitis at onset was uncommon (<5%). Median time to relapse was 14 m…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)